Navigating bottlenecks in cell therapy manufacturing: A versatile and scalable platform solution

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Navigating bottlenecks in cell therapy manufacturing: A versatile and scalable platform solution

As cell therapies quickly advance from pre-clinical stage into clinical and commercial applications, the design and implementation of scalable manufacturing platform technologies continues to be a focus for the field. Despite the successful commercialization of several cell therapies, bottlenecks in manufacturing throughput and capacity continue to hinder patient access to these life-saving treatments.

This webinar will explore the current landscape and limitations of cell therapy manufacturing platforms and share insights into how to choose a technology platform that assures flexibility in process development and scalability for clinical and commercial success.

Challenges and opportunities associated with current cell therapy manufacturing platforms
The flexibility of translating CAR T manufacturing processes to the Lonza Cocoon^® Platform
How to ensure process flexibility that enables rapid implementation of iterative manufacturing improvements

Peter Yates

Director, Product Management - Personalized Medicine, Lonza

Peter Yates is the Director of Product Management for Lonza’s Personalized Medicine Business Unit. Peter earned a doctorate in Microbiology and Molecular Immunology from the University of Southern California in 2013 where he studied epigenetic regulation of hematopoietic development. Joining Lonza in early 2021, Peter’s focus is on the continued development and advancement of the Cocoon® Platform, a closed and automated cell therapy manufacturing solution.